行情

CRBP

CRBP

Corbus制药控股
NASDAQ

实时行情|Nasdaq Last Sale

0.8223
+0.0217
+2.71%
盘后: 0.8005 -0.0218 -2.65% 19:14 12/02 EST
开盘
0.8100
昨收
0.8006
最高
0.8440
最低
0.7700
成交量
106.47万
成交额
--
52周最高
4.000
52周最低
0.7700
市值
1.03亿
市盈率(TTM)
-2.0491
分时
5日
1月
3月
1年
5年
Corbus Pharmaceuticals 每股收益超过 0.10 美元,收入低于预期
Corbus Pharmaceuticals (NASDAQ:CRBP): Q3 GAAP EPS of -$0.02 beats by $0.10. Revenue of $0.1M (-91.9% Y/Y) misses by $0.43M. Press Release As of September 30, 2021, the company has $108M
Seekingalpha · 11/12 13:18
BRIEF-Corbus Pharma Reports Q3 Loss Per Share Of $0.02
reuters.com · 11/12 13:13
Corbus Pharmaceuticals Q3 EPS $(0.02) Up From $(0.43) YoY
Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(0.02) per share. This is a 95.35 percent increase over losses of $(0.43) per share from the same period last year.
Benzinga · 11/12 13:10
Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat at the Jefferies London Healthcare Conf...
PR Newswire · 11/11 13:05
Will Corbus Pharmaceuticals (CRBP) Report Negative Q3 Earnings? What You Should Know
Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 11/02 19:02
uniQure 宣布任命 Rachelle Jacques 为董事会成员
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Rachelle Jacques to its Board of Directors. Ms. Jacques, who will serve on the Board's...
GlobeNewswire · 10/21 13:30
2021 年 10 月 5 日的顶级大麻推动者
GAINERS: Tetra Bio Pharma (OTC:TBPMF) shares closed up 21.96% at $0.22 with an estimated market cap of $88.1M.
Benzinga · 10/05 21:45
2021 年 9 月 13 日大麻股票的上涨和下跌
GAINERS: Cipher Pharms Inc (OTC:CPHRF) shares closed up 13.17% at $2.13 with an estimated market cap of $56.4M.
Benzinga · 09/13 20:43
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解CRBP最新的财务预测,通过CRBP每股收益,每股净资产,每股现金流等数据分析Corbus制药控股近期的经营情况,然后做出明智的投资选择。
分析师评级

4位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

0.00%强力推荐
25.00%买入
75.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测CRBP价格均价为1.987,最高价位3.000,最低价为0.9600。
最高3.000
均价1.987
最低0.9600
现价0.8223
EPS
实际EPS
预期EPS
-0.20-0.15-0.10-0.05
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 165
机构持股: 5,120.23万
持股比例: 40.89%
总股本: 1.25亿
类型机构数股数
增持
22
181.89万
建仓
12
47.60万
减持
29
542.15万
平仓
23
170.01万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+0.49%
制药与医学研究
-0.06%
高管信息
Chairman/Independent Director
Alan Holmer
Chief Executive Officer/Director
Yuval Cohen
Chief Financial Officer
Sean Moran
Chief Operating Officer
Craig Millian
Independent Director
Avery Catlin
Independent Director
Rachelle Jacques
Independent Director
John Jenkins
Independent Director
Peter Salzmann
暂无数据
CRBP 简况
Corbus Pharmaceuticals Holdings, Inc.是一家主要从事开发和商业化治疗罕见、慢性及严重炎症与纤维化疾病的新型治疗剂业务的三期临床阶段制药公司。该公司通过开发和商业化治疗药物来治疗罕见的危及生命的炎症性纤维化疾病。该公司先导产候选品lenabasum是一种新型合成口服内源性大麻素模拟药物,旨在解决慢性炎症并阻止纤维化进程。lenabasum刺激产生消炎的专用消脂剂(SPM),并通过激活内源性途径来阻止纤维化。该公司正在开发治疗系统性硬化症、囊性纤维化、弥漫性皮肤、皮肤占优势的皮肌炎和系统性红斑狼疮(SLE)等5种疾病的药物。

微牛提供Corbus Pharmaceuticals Holdings Inc(NASDAQ-CRBP)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CRBP股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CRBP股票基本功能。